Saudi Journal of Kidney Diseases and Transplantation

: 2011  |  Volume : 22  |  Issue : 4  |  Page : 805-

Tumor marker and hemodialysis

Viroj Wiwanitkit 
 Wiwanitkit House, Bangkhae, Bangkok, 10160, Thailand

Correspondence Address:
Viroj Wiwanitkit
Wiwanitkit House, Bangkhae, Bangkok, 10160

How to cite this article:
Wiwanitkit V. Tumor marker and hemodialysis.Saudi J Kidney Dis Transpl 2011;22:805-805

How to cite this URL:
Wiwanitkit V. Tumor marker and hemodialysis. Saudi J Kidney Dis Transpl [serial online] 2011 [cited 2021 Apr 16 ];22:805-805
Available from:

Full Text

To the Editor,

I read the report on tumor marker level in a hemodialysis (HD) case with great interest. [1] Tzitzikos et al concluded that measurement of some tumor markers such as alfa-fetoprotein may be beneficial in HD patients. [1] Indeed, the use of tumor marker in HD has a great variability due to the dialysis process. [2] Differences in the amounts of tumor marker levels in the different phases of dialysis can be seen. [2] Regarding this report, [1] there are some considerations. First, the number of subjects is few and there is no matched control group for comparison. Second, each tumor marker has its specific background in laboratory analysis. Different physiological and pathological factors affect the analytical results differently. Focusing on the patients undergoing HD in this study, there is no information on complete background (demographic, laboratory and clinical parameters) and the question that remains is whether there is a normal distribution of those underlying parameters.


1Tzitzikos G, Saridi M, Filippopoulou T, et al. Measurement of tumor markers in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2010;21(1):50-3.
2Kuno T, Kaizu K. Use of tumor markers in patients on chronic hemodialysis. Nippon Rinsho 2004;62(Suppl 6):391-4.